Cohort · P2-CRC-D0918Active studySynthetic mock data
ctDNA MRD-negative sub-cohort
Owner ML · last updated 2026-04-12
Size
23
Status
draft
Inclusion criteria
2
Exclusion criteria
1
Definition
Inclusion
- +Stage III CRC s/p curative resection
- +Undetectable ctDNA at week 4 post-op
Exclusion
- −Inadequate surgical margin
draftP2-CRC-D0918Owner MLLast updated 2026-04-12
Enrollment over time
From wk 0 (n=0) to wk 16 (n=23)
Subjects in cohort (8)
| Subject | MRN | Age / Sex | Site | Enrolled | Status |
|---|---|---|---|---|---|
| CRC-MRDN-001 Maria Alvarez | MRN 6025400 | 48 / F | Site 03 — Chicago | 2025-10-04 | withdrawn |
| CRC-MRDN-002 Henry Müller | MRN 6025401 | 51 / M | Site 09 — Munich | 2025-10-09 | active |
| CRC-MRDN-003 Rachel Sørensen | MRN 6025402 | 54 / F | Site 12 — Singapore | 2025-10-14 | active |
| CRC-MRDN-004 Robert Adebayo | MRN 6025403 | 57 / M | Site 14 — Boston | 2025-10-19 | active |
| CRC-MRDN-005 Priya Iversen | MRN 6025404 | 60 / F | Site 18 — Toronto | 2025-10-24 | active |
| CRC-MRDN-006 Theo O'Connor | MRN 6025405 | 63 / M | Site 22 — Madrid | 2025-10-29 | active |
| CRC-MRDN-007 Sara Tanaka | MRN 6025406 | 66 / F | Site 03 — Chicago | 2025-11-03 | active |
| CRC-MRDN-008 Antonio Marquez | MRN 6025407 | 69 / M | Site 09 — Munich | 2025-11-08 | active |
Linked study
P2-CRC-D0918
ctDNA-guided adjuvant de-escalation
Recurrence-free survival, 24 mo · 87/160 enrolled
Sister cohorts in P2-CRC-D0918
Endpoints attached to this protocol
Cross-links